**Author Information** An event is serious (based on the ICH definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* other medically important event

In a study involving hospitalised patient with Coronavirus disease 2019 (Covid-19) due to severe acute respiratory coronavirus 2 (SARS-CoV-2) received compassionate use of remdesivir between 25 January 2020 7 March 2020, four patients \[*ages and sexes not stated*\], who developed multiple organ failure, elevated aminotransferases, maculopapular rash or worsening of pre-existing renal failure \[*duration of treatment to reactions onsets and outcomes not stated*\].

The patients, who were hospoitalised for Covid-19 due to SARS-CoV-2, started receiving a 10 day course of IV remdesivir (Gilead Sciences) comprising 200mg on day 1 and 100mg daily for the following 9 days. One of these four patients, had pre-existing renal failure. Subsequently, two patients developed multi-organ failure (n=1) or worsening of pre-existing renal failure (n=1). The remanining two patients showed elevated levels of aminotransferases, of whom one patient additionally had maculopapular rash.

Therefore, all the patients discontinued remdesivir therapy.
